The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Open accessAbstract
Purpose COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. Methods PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. Results We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro. Conclusions There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 1×
“The results of these trials will be the fi rst available on humans, since studies published to date on the characteristics and management of patients with COVID-19 did not report dataabout chloroquineuse[1,12 – 15].”
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · cited 1×
“The results of these trials will be the first available on humans, since studies published to date on the characteristics and management of patients with COVID-19 did not report data about chloroquine use [1, [12] [13] [14] [15] .”
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Colson, P., Rolain, J.-M., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 468
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
(2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0019 · Cited by 189
Ethical and legal framework and regulation for off-label use: European perspective
Lenk, C., & Duttge, G. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40232 · Cited by 96
Hage-Melim, L. I. D. S., Federico, L. B., de Oliveira, N. K. S., Francisco, V. C. C., Correia, L. C., de Lima, H. B., Gomes, S. Q., Barcelos, M. P., Francischini, I. A. G., & da Silva, C. H. T. D. P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117963 · Cited by 91
Cardiac effects and toxicity of chloroquine: a short update
Mubagwa, K. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106057 · Cited by 78
Repurposing old drugs as antiviral agents for coronaviruses
Yang, C., Peng, T.-T., Hsu, H., Lee, Y., Wu, S.-H., Lin, W., Ke, Y., Hsu, T., Yeh, T., Huang, W.-Z., et al. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.05.003 · Cited by 71
Tackling SARS-CoV-2: Proposed Targets and Repurposed Drugs
Joshi, S. S., Joshi, M., & Degani, M. S. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0147 · Cited by 68
Novel coronavirus pandemic: A global health threat
Abu-Zidan, F., Khan, G., Sheek‐Hussein, M., Alsuwaidi, A. R., & Idris, K. M. (2020) · Turkish Journal of Emergency Medicine · doi:10.4103/2452-2473.285016 · Cited by 67
SARS-CoV-2 Infection and the Newborn
Ovalı, F. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00294 · Cited by 64
Convertino, I., Tuccori, M., Ferraro, S., Valdiserra, G., Cappello, E., Focosi, D., & Blandizzi, C. (2020) · Critical Care · doi:10.1186/s13054-020-03020-3 · Cited by 58
Diacerein: A potential multi-target therapeutic drug for COVID-19
de Oliveira, P. G., Termini, L., Durigon, E. L., Lepique, A. P., Sposito, A. C., & Boccardo, E. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109920 · Cited by 44
Mechanisms of Myocardial Injury in Coronavirus Disease 2019
Rali, A. S., Ranka, S., Shah, Z. I., & Sauer, A. J. (2020) · Cardiac failure review · doi:10.15420/cfr.2020.10 · Cited by 37
Shi, Q., Zhou, Q. X., Wang, X., Liao, J., Yang, Y. P., Wang, Z., Lu, S., Ma, Y., Xun, Y., Luo, X., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3301 · Cited by 15
Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19
Adeel, A. (2020) · Sudanese Journal of Paediatrics · doi:10.24911/sjp.106-1587122398 · Cited by 14
Pati, S. B. B., & Houston, T. (2020) · Epilepsy Research · doi:10.1016/j.eplepsyres.2020.106399 · Cited by 11
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06022-5 · Cited by 2,105
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004363 · Cited by 1,565
COVID‐19 diagnosis and management: a comprehensive review
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., & Agrò, F. E. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13091 · Cited by 1,369
Metadata
- Authors
- Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S.
- Venue
- Journal of Critical Care
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 57
- Pages
- 279-283
- ISSN
- 0883-9441 (ISSN-L)
- OpenAlex
- W3009389929
- Cited by
- 1,160
- References
- 24
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.